Antimycobacterial therapy

Mayo Clinic Proceedings

Volumn 74, Issue 10, 1999, Pages 1038-1048

  Van Scov, Robert E ^a   Wilkowskk, Conrad J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; GENTAMICIN; ISONIAZID; PYRAZINAMIDE; PYRIDOXINE DERIVATIVE; RIFABUTIN; RIFAMATE; RIFAMPICIN; RIFATER; STREPTOMYCIN;

CONFERENCE PAPER; DRUG METABOLISM; DRUG MONITORING; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNE DEFICIENCY; LIVER TOXICITY; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; OTOTOXICITY; PRACTICE GUIDELINE; PREGNANCY; PRIMARY MEDICAL CARE; TREATMENT INDICATION; TUBERCULOSIS;

EID: 0032842431     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)64004-4     Document Type: Conference Paper

References (43)

1. World Health Organization, Global Tuberculosis Programme. Global Tuberculosis Control: WHO Report 1998. Geneva: World Health Organization; 1998. (Publication No. WHO/TB/98-237)
2. Murray CJL, Salomon JA. Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci USA 1998;95:13881-13886
3. American Thoracic Society and Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994:149:1359-1374
4. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Core Curriculum on Tuberculosis. 3rd ed. 1994. Available at: http://www.cdc.gov/nchstp/tb/pubs/corecurr.htm. Accessed July 20, 1999
5. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR Morb Mortal Wkfy Rep 1994;43(RR-13):1132
6. Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chalsson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996:154:1013-1019
7. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkfy Rep 1998;47(RR-20):l-58
8. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkfy Rep 1996;45:(RR-4):118
9. American Thoracic Society Workshop. Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med 1997;155:1804-1814
10. French AL, Senator DA, Gordin FM. Nontuberculous mycobacterial infections. Med Clin North Am 1997 Mar;81:361-379
11. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Crit Care Med 1997;156:S1-S25
12. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome. Chest 1992:101:1605-1609
13. Telrstein AS, Damsker B, Kirschner PA, Krellenstein DJ, Robinson B, Chuang MT. Pulmonary infection with Mycobacterium aviumintrace/lulare: diagnosis, clinical patterns, treatment. Mt Sinai J Med 1990:57:209-215
14. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, et al (Canadian HIV Trials Network Protocol 010 Study Group). A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. W Engl J Med 1996:335:377-383
15. Havlir DV, Dubé MP, Sanier FR, Forthal DN, Kemper CA, Dünne MW, et al (California Collaborative Treatment Group). Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. W Engl J Med 1996:335:392-398
16. 1997 USPHS/IDSA guidelines forthe prevention of opportunistic infections in persons Infected with human immunodeficiency virus. Ann Intern Med 1997:127:922-946
17. Horowltz EA, Sanders WE Jr. Other Mycobacterium species. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. Vol 2. 4th ed. New York: Churchill Livingstone; 1995. pp 2264-2273
18. Griffith DE, Wallace RJ Jr. New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Semin Respir Infect 1996:11:301-310
19. Sauret J, Hernandez-Flix S, Castro E, Hernandez L, Ausina V, Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. Tuber Lung Dis 1995:76:104-108
20. Edelstein H. Mycobacterium marinum skin infections: report of 31 cases and review of the literature. Arch Intern Med 1994; 154:1359-1364
21. Ljungberg B, Chrlstensson B, Grubb R. Failure of doxycyclme treatment in aquarium-associated Mycobacterium marinum infections. Scand J Infect Dis 1987;19:539-543
22. Iredell J, Whttby M, Blacklock Z. Mycobacterium marinum infection: epidemiology and presentation in Queensland 1971-1990. Med J Aust 1992:157:596-598
23. Bonnet E, Debat-Zoguereh D, Petit N, Ravaux l, Gallais H. Clarithromycin: a potent agent against infections due to Mycobacterium marinum [letter]. Clin Infect Dis 1994:18:664-666
24. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser 1998:874:1-43
25. Mandell GL, Pétri WA Jr. Drugs used in the chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. pp 1155-1174
26. Bowersox DW, Winterbauer RH, Stewart GL, Orme B, Barron E. Isoniazid dosage in patients with renal failure. N Engl J Med 1973; 289:84-87
27. Mltcnell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrel! JA, Snodgrass WR, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976:84:181-192
28. Moulding T, Iseman M, Sbarbaro J. Preventing isoniazid hepatotoxicity [letter]. Ann Intern Med 1976:85:398-399
29. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981:1:171-174
30. Isoniazid-associated hepatitis: summary of the report of the Tuberculosis Advisory Committee and special consultants to the director, Centers for Disease Control. MMWR Morb Mortal Wkly Rep 1974:23:97-98
31. Bailey WC. Welll H, DeRouen TA, Zlskind MM, Jackson HA, Greenberg HB. The effect of isoniazid on transaminase levels. Ann Intern Med 1974:81:200-202
32. Whtttington HG, Grey L. Possible interaction between disulfiram and isoniazid. Am J Psychiatry 1969:125:1725-1729
33. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 1990:113:799-800
34. Strayhorn VA, Baclewicz AM, Self TH. Update on rifampin drug interactions, III. Arch Intern Med 1997;157:2453-2458
35. Poole G, Stradling P, Worlledge S. Potentially serious side effects of high-dose twice-weekly rifampicin. BMJ 1971;3:343-347
36. Petrowskl JT III. Uveitis associated with rifabutin therapy: a clinical alert. J Am Optom Assoc 1996:67:693-696
37. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978; 59:13-32
38. Citron KM, Thomas GO. Ocular toxicity from ethambutol [editorial]. Thorax 1986;41:737-739
39. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc 1999; 74:519-528
40. Walker RC. The fluoroquinolones. Mayo Clin Proc 1999:74:1030-1037
41. Smllack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999:74:730-734
42. Smllack JD. The tetracyclines. Mayo Clin Proc 1999:74:727-729
43. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999;74:613-634